Page last updated: 2024-12-11
integramide a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
integramide A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Research Excerpts
Overview
Integramide A is a 16-mer long, effective peptaib inhibitor of HIV-1 integrase.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Integramide A is a 16-amino acid peptide inhibitor of the enzyme HIV-1 integrase. " | ( Total synthesis, characterization, and conformational analysis of the naturally occurring hexadecapeptide integramide A and a diastereomer. Broxterman, QB; Brückner, H; Crisma, M; Damato, F; De Zotti, M; Felock, PJ; Formaggio, F; Hazuda, DJ; Kaptein, B; Kirschbaum, J; Mammi, S; Schievano, E; Singh, SB; Toniolo, C, 2010) | 2.02 |
| "Integramide A is a 16-mer long, effective peptaib inhibitor of HIV-1 integrase." | ( Triple Hyp→Pro replacement in integramide A, a peptaib inhibitor of HIV-1 integrase: Effect on conformation and bioactivity. Broxterman, QB; De Borggraeve, W; De Zotti, M; Felock, PJ; Formaggio, F; Hazuda, DJ; Kaptein, B; Singh, SB; Toniolo, C, 2011) | 1.38 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||